Citius Pharmaceuticals (NASDAQ:CTXR) Rating Lowered to “Sell” at Wall Street Zen

Citius Pharmaceuticals (NASDAQ:CTXR) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

A number of other brokerages have also issued reports on CTXR. D. Boral Capital reissued a “buy” rating and issued a $6.00 price target on shares of Citius Pharmaceuticals in a report on Wednesday, March 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Friday, March 27th. HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Citius Pharmaceuticals in a report on Monday, May 18th. Finally, Zacks Research raised shares of Citius Pharmaceuticals to a “hold” rating in a report on Tuesday, May 19th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $5.00.

Citius Pharmaceuticals Stock Down 5.0%

Shares of NASDAQ:CTXR opened at $0.56 on Friday. The stock has a market cap of $15.37 million, a PE ratio of -0.26 and a beta of 1.03. The company’s fifty day moving average is $0.72 and its 200 day moving average is $0.84. Citius Pharmaceuticals has a 52 week low of $0.48 and a 52 week high of $2.48.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its earnings results on Friday, May 15th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.67). Sell-side analysts anticipate that Citius Pharmaceuticals will post -1.87 EPS for the current year.

Institutional Investors Weigh In On Citius Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in CTXR. Heights Capital Management Inc. bought a new stake in shares of Citius Pharmaceuticals during the 4th quarter valued at about $622,000. XTX Topco Ltd boosted its stake in shares of Citius Pharmaceuticals by 572.8% during the 4th quarter. XTX Topco Ltd now owns 107,118 shares of the company’s stock valued at $83,000 after purchasing an additional 91,196 shares in the last quarter. Asset Advisory Group Inc. bought a new stake in shares of Citius Pharmaceuticals during the 4th quarter valued at about $46,000. Finally, NewEdge Advisors LLC bought a new stake in shares of Citius Pharmaceuticals during the 2nd quarter valued at about $40,000. Institutional investors own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.